← Oncology Approval Tracker

FDA DECISION ·

Vegzelma

bevacizumab-adcd · Celltrion

Biosimilar approvalBiosimilarMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Bevacizumab biosimilar for labeled uses in colorectal cancer, nonsquamous NSCLC, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube or primary peritoneal cancer.

LAMPGEN ANALYSIS

Why it matters

The product adds a bevacizumab option for regimens across six cancer categories.

What research teams should watch

Check the disease-specific labeled partner drugs and capture the biosimilar suffix in treatment and safety records.

PRIMARY RECORDS

Sources